Abstract
Stem cell therapy for Parkinson's disease requires demonstration of safety and efficacy of dopaminergic cells derived from a cell line, consideration of dose, and whether this is deliverable at scale. Park etal. demonstrate these requirements for a new hESC line and that their manufacturing methods allow for its scalability.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have